USP44 Promoter Methylation in Plasma Cell-Free DNA in Prostate Cancer

Londra, Dora; Mastoraki, Sophia; Bournakis, Evangelos; Zavridou, Martha; Thanos, A.; Ράμπιας, Θεόδωρος; Lianidou, Evi

doi:10.3390/cancers13184607

Cited by 8 publications

(5 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interrogation of a panel of ctDNA methylation markers in post-surgery colon cancer patients has been shown to be predictive of recurrence with good accuracy ( Jin et al, 2021 ). Similarly, methylation levels of specific marker USP44 has been associated with disease-free survival in prostate adenocarcinoma patients ( Londra et al, 2021 ). Interestingly, WGBS approach has been used to assess the methylation profile of single CTCs and CTC clusters in BC patients, revealing specific hypomethylation of proliferation and stemness regulators binding sites only in CTC clusters.…”

Section: Epigenomicsmentioning

confidence: 99%

Enhancing clinical potential of liquid biopsy through a multi-omic approach: A systematic review

et al. 2023

View full text Add to dashboard Cite

In the last years, liquid biopsy gained increasing clinical relevance for detecting and monitoring several cancer types, being minimally invasive, highly informative and replicable over time. This revolutionary approach can be complementary and may, in the future, replace tissue biopsy, which is still considered the gold standard for cancer diagnosis. “Classical” tissue biopsy is invasive, often cannot provide sufficient bioptic material for advanced screening, and can provide isolated information about disease evolution and heterogeneity. Recent literature highlighted how liquid biopsy is informative of proteomic, genomic, epigenetic, and metabolic alterations. These biomarkers can be detected and investigated using single-omic and, recently, in combination through multi-omic approaches. This review will provide an overview of the most suitable techniques to thoroughly characterize tumor biomarkers and their potential clinical applications, highlighting the importance of an integrated multi-omic, multi-analyte approach. Personalized medical investigations will soon allow patients to receive predictable prognostic evaluations, early disease diagnosis, and subsequent ad hoc treatments.

show abstract

Section: Epigenomicsmentioning

confidence: 99%

Enhancing clinical potential of liquid biopsy through a multi-omic approach: A systematic review

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Prediction value of DNA methylation markers in tissue has already been well verified; recently the potential of ctDNA methylation-based biomarkers for predicting PCa prognosis was also confirmed, with methylations of USP44 [ 113 ], APC [ 114 ], GSTP1 [ 114 ], EDNRB [ 115 ], MDR1 [ 115 ], ZNF660 [ 116 ], and RARβ2 [ 117 ] have been reported to be more common in late-stage or recurrent patients compared to early-stage PCa patients. Methylation at these sites is associated with a worse prognosis.…”

Section: Cfdna In Pca Risk Stratification and Monitoringmentioning

confidence: 99%

Cell-free DNA in the management of prostate cancer: Current status and future prospective

He¹,

Xiao²,

Shi

et al. 2023

Asian Journal of Urology

View full text Add to dashboard Cite

“…Most of these studies have been carried out on lung cancer [80,[99][100][101][102] and colorectal cancer [81,103], including the use of DNA methylation analysis [104]. However, other types of cancer, such as ovarian cancer [84], prostate cancer [82,105], pancreatic ductal adenocarcinoma [106], melanoma [107], and others [88,89,[108][109][110], have also been widely represented in the works carried out in recent years.…”

Section: Possible Applications Of Ctdna In Oncologymentioning

confidence: 99%

Circulating Tumor DNA Is a Variant of Liquid Biopsy with Predictive and Prognostic Clinical Value in Breast Cancer Patients

Zavarykina,

Lomskova,

Pronina

et al. 2023

IJMS

View full text Add to dashboard Cite

This paper introduces the reader to the field of liquid biopsies and cell-free nucleic acids, focusing on circulating tumor DNA (ctDNA) in breast cancer (BC). BC is the most common type of cancer in women, and progress with regard to treatment has been made in recent years. Despite this, there remain a number of unresolved issues in the treatment of BC; in particular, early detection and diagnosis, reliable markers of response to treatment and for the prediction of recurrence and metastasis, especially for unfavorable subtypes, are needed. It is also important to identify biomarkers for the assessment of drug resistance and for disease monitoring. Our work is devoted to ctDNA, which may be such a marker. Here, we describe its main characteristics and potential applications in clinical oncology. This review considers the results of studies devoted to the analysis of the prognostic and predictive roles of various methods for the determination of ctDNA in BC patients. Currently known epigenetic changes in ctDNA with clinical significance are reviewed. The possibility of using ctDNA as a predictive and prognostic marker for monitoring BC and predicting the recurrence and metastasis of cancer is also discussed, which may become an important part of a precision approach to the treatment of BC.

show abstract

USP44 Promoter Methylation in Plasma Cell-Free DNA in Prostate Cancer

Cited by 8 publications

References 34 publications

Enhancing clinical potential of liquid biopsy through a multi-omic approach: A systematic review

Enhancing clinical potential of liquid biopsy through a multi-omic approach: A systematic review

Cell-free DNA in the management of prostate cancer: Current status and future prospective

Circulating Tumor DNA Is a Variant of Liquid Biopsy with Predictive and Prognostic Clinical Value in Breast Cancer Patients

Contact Info

Product

Resources

About